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Abstract  25 
Background: Studies have shown increased gastric cancer risk in users of proton pump 26 
inhibitors (PPI) and histamine-2 receptor antagonists, questioning the safety of gastric acid 27 
suppression. Therefore, we conducted a case-control study within the Scottish Primary Care 28 
Clinical Informatics Unit (PCCIU) database and a cohort study in UK Biobank.  29 
Methods: In PCCIU, five controls were matched to cases diagnosed 1999 to 2011 and 30 
medications were determined from GP records. Odds ratios (OR) and 95% confidence 31 
intervals (CI) were calculated using conditional logistic regression. In UK Biobank, 32 
medications were self-reported at cohort entry 2006 to 2010 and gastric cancer ascertained 33 
from cancer-registries until 2014. Hazard ratios (HR) were calculated using Cox regression.  34 
Results: PCCIU contained 1,119 cases and 5,394 controls. UK Biobank contained 250 cases 35 
in 471,779 participants. PPI users had a higher gastric cancer risk in PCCIU and UK Biobank 36 
when applying a one year lag (adjusted OR=1.49, 95% CI 1.24, 1.80; adjusted HR=1.28, 95% 37 
CI 0.86, 1.90, respectively) but these associations were attenuated when using a two year lag 38 
(adjusted OR=1.13, 95% CI 0.91, 1.40; adjusted HR=1.15, 95% CI 0.73, 1.82, respectively).  39 
Conclusions: Overall, we observed little consistent evidence of an increased risk of gastric 40 
cancer with PPI use. 41 
 42 
  43 
Background 44 
Gastric cancer is the fifth most common cancer worldwide with over a million newly 45 
diagnosed cases in 2018 and is the third leading cause of cancer mortality accounting for over 46 
782,000 deaths globally1. These high incidence and mortality rates highlight the importance 47 
of preventing gastric cancer.  48 
Proton pump inhibitors (PPI) and histamine-2 receptor antagonists (H2RA) are widely 49 
prescribed for the treatment of gastric diseases such as peptic ulcer, dyspepsia, gastro-50 
oesophageal reflux disease (GORD) and Helicobacter Pylori (H. pylori) infection. The safety 51 
of long-term acid suppression has long been debated2 and various mechanisms are of 52 
particular concern to gastric cancer risk. Acid suppression has been shown to cause excess 53 
blood gastrin levels3, which has been suggested to lead to hyperplasia of enterochromaffin 54 
cells and ultimately gastric carcinoid formation4. PPI and H2RA reduce the acid content of 55 
gastric acid causing hypochlorhydria which can lead to an overgrowth of bacteria in the gut, 56 
reducing the absorption of nutrients and lowering protection against infections5,6. Finally, it 57 
has been suggested PPI could interact with H. pylori leading to greater acid suppression 58 
causing H. pylori and non-H. pylori bacterial overgrowth which cause or exacerbate gastritis, 59 
something which is associated with increased gastric cancer risk7,8.  60 
Consequently, the association between PPI and gastric cancer risk has been investigated in 61 
observational studies and a recent meta-analysis showed an increase in gastric cancer risk of 62 
150% with prolonged PPI use9. Similarly, H2RA use has also been shown to increase gastric 63 
cancer risk by 40% in a recent meta-analysis10. However, some of the individual studies in 64 
this meta-analyses did not adjust for important confounders and most incorporated short lag 65 
times, with three not using any lag in their main analysis11–13. Lag times are recommended in 66 
studies of drug-cancer associations14 because (a) cancer, including gastric cancer15, develops 67 
over a prolonged period of time, and medications newly prescribed in the short period before 68 
cancer diagnosis are unlikely to be causative; and, (b) medications prescribed immediately 69 
before cancer diagnosis could reflect reverse causality, as pre-diagnostic cancer symptoms 70 
may lead to the prescription of medications16. Relatively short lags are thought to be 71 
sufficient to avoid bias from reverse causation, but the relevant lag time to address the 72 
induction and latency period is unclear and it is therefore recommended that a range of lags 73 
are used14.  74 
Previous studies have raised concerns in both patients and practitioners about the use or 75 
prescribing of acid suppressing medications17. Therefore, we investigated whether PPI or 76 
H2RA use was associated with increased gastric cancer risk in two large independent 77 
population-based studies in the United Kingdom (UK). Importantly, we adjusted for a wide 78 
range of confounders and explored the potential for reverse causation using lags of various 79 
duration. 80 
 81 
  82 
Methods 83 
Primary Care Clinical Informatics Unit database 84 
Data source  85 
The Primary Care Clinical Information Unit (PCCIU) database is a computerized primary 86 
care dataset in Scotland, capturing approximately 15% of the Scottish general practice (GP) 87 
registered population18. The PCCIU database collected electronic medical records between 88 
1993 and 2011 and captured demographic information, diagnoses (using Read codes19), 89 
referrals, prescriptions and other information (including smoking, alcohol intake and body 90 
mass index [BMI: kg/m2]). Access to the data was obtained following an application to the 91 
Research Applications and Data Management Team, University of Aberdeen. Ethical 92 
approval for this study was supplied by the Queen’s University Belfast, School of Medicine, 93 
Dentistry and Biomedical Sciences Research Ethics Committee (reference number: 15.43). 94 
Study design 95 
A nested case-control study was conducted within the PCCIU database. Individuals with 96 
newly diagnosed primary gastric cancer (Read code as B11) between 1 January 1999 and 30 97 
April 2011 were identified as cases. Up to five controls were matched to each case on age, 98 
sex and GP practice, to form a case-matched set. We defined the index date as the cancer 99 
diagnosis date in each case-matched set. Cases and controls with any previous cancer 100 
diagnoses (apart from non-melanoma skin cancer) before the index date were excluded. 101 
In this study, the start of prescription records was from 1 January 1996 as prescriptions before 102 
this time were less likely to be recorded electronically, or the date of GP registration if this 103 
occurred after 1 January 1996. The shortest duration of prescription records was identified 104 
within each matched set. The start of the exposure period was then set as the index date 105 
minus this shortest duration within each matched set of a case and controls to ensure all 106 
members of the matched set had an identical length of exposure period. The exposure period 107 
ended one year prior to the index date, to reduce the risk of reverse causality and exclude 108 
medications which are unlikely to have caused the cancer20. In the main analysis we excluded 109 
individuals who had less than three years of records prior to their index date. Additionally, 110 
gastric cancer cases without matched controls were excluded.  111 
Definition of exposure  112 
An individual was considered a medication user based upon any prescriptions in the exposure 113 
period. PPI were: esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole 114 
sodium; and H2RA were: cimetidine, famotidine, nizatidine, or ranitidine, as listed within the 115 
British National Formulary21. Drug quantity and strength from prescription records were used 116 
to calculate the number of Defined Daily Doses (DDD) for each prescription using World 117 
Health Organization methodology22,23. High-dose PPI use was estimated based upon the 118 
National Institute for Health and Care Excellence guidelines24. We identified the high-dose 119 
PPI users if they were ever prescribed 40mg-esomeprazole, 40mg-rabeprazole, or 40mg-120 
omeprazole at least once daily, or 30mg-lansoprazole or 40mg-pantoprazole at least twice 121 
daily.  122 
Covariates  123 
We determined lifestyle risk factors from codes in electronic GP records, using the most 124 
recent entries prior to the index date. Smoking status (never, former, or current smokers), 125 
alcohol consumption (none, low e.g. moderate or light drinker, or high intake e.g. above 126 
recommended limits, chronic alcoholism) and obesity (BMI>30, or not obese) were 127 
extracted. Comorbidities during the exposure period were also identified from GP records, 128 
including diabetes, coronary heart disease, myocardial infarction, heart failure, peripheral 129 
vascular disease, cerebrovascular disease, cerebrovascular accident, chronic obstructive 130 
pulmonary disease, mental illness, liver disease, oesophagitis, and peptic ulcer. GP postcodes 131 
were used to estimate social deprivation on the basis of the Scottish Index of Multiple 132 
Deprivation25. Any aspirin or statin use in the exposure period were identified as previous 133 
studies have shown associations between these medications and gastric cancer risk26–28.  134 
Statistical analysis 135 
In the PCCIU database, we used conditional logistic regression to estimate odd ratios (OR) 136 
and 95% confidence intervals (CI) for the association between PPI or H2RA use and gastric 137 
cancer risk. The matched design accounted for age, sex and GP practice, then we adjusted for 138 
obesity, aspirin and statin use, and comorbidities including diabetes, coronary heart disease, 139 
myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, 140 
cerebrovascular accident, chronic obstructive pulmonary disease, mental illness, liver disease, 141 
oesophagitis, and peptic ulcer. Furthermore, we repeated the analysis additionally adjusting 142 
for smoking status and alcohol consumption (in individuals for whom this data was 143 
available). Dose-response analyses were conducted based upon DDD and the number of 144 
prescriptions (365 DDD or 12 prescriptions approximately corresponded to one year of issued 145 
medication). We categorised users as 1-183 DDD, 184-365 DDD, 366-1095 DDD or more 146 
than 1095 DDD. Similarly, number of prescriptions was divided into four categories as 1-6 147 
prescriptions, 6-12 prescriptions, 12-36 prescriptions and more than 36 prescriptions. An 148 
analysis was conducted to investigate high-dose PPI use and gastric cancer risk as a previous 149 
study suggested that high-dose PPI may have potential anticancer properties but not low-dose 150 
PPI29. We also conducted an analysis adjusting for H2RA and PPI simultaneously. An active 151 
comparator analysis was conducted by comparing PPI users to users of only H2RA in the 152 
exposure period. A similar active comparator analysis was conducted comparing H2RA users 153 
to only PPI users in the exposure period. Additionally, we conducted an analysis removing 154 
peptic ulcer and oesophagitis from the main model, as these could lie on the causal pathway. 155 
Moreover, we conducted a sensitivity analysis using multiple imputation with chained 156 
equations to adjust for missing smoking and alcohol values as the main analysis used a 157 
complete case approach30. The imputation model for smoking category used ordered logit 158 
models for cases and controls separately, adjusted for age, sex, GP practice, PPI (or H2RA), 159 
obesity, comorbidities (as mentioned above), statins and aspirin. Twenty-five imputations 160 
were conducted and results were combined using Rubin’s rules31. The same methods were 161 
utilised for alcohol imputation. We also conducted a sub-group analysis by sex using 162 
interaction terms within the models to compare associations by sex.  163 
Sensitivity analyses were conducted varying the duration of lag investigated as 164 
recommended14,32. Specifically, we conducted a series of analyses by removing prescriptions 165 
in the two years (including only individuals with at least four years of GP records), three 166 
years (including only individuals with at least five years of GP records), four years (including 167 
only individuals with at least six years of GP records), and five years (including only 168 
individuals with at least seven years of GP records) prior to index date, separately. Next, 169 
analyses were conducted investigating medication use in one year intervals before gastric 170 
cancer diagnosis/index date. Specifically we identified the users in the year before the index 171 
date (including individuals with at least three years of records), in the period of one to two 172 
years before the index date (including individuals with at least three years of records), in the 173 
period of two to three years before the index date (including individuals with at least four 174 
years of records), in the period of three to four years before the index date (including 175 
individuals with at least five years of records), and in the period of four years to five years 176 
before the index date (including individuals with at least six years of records). Additionally, 177 
we conducted an analysis comparing new use of PPI/H2RA in the year before index date 178 
(including individuals with at least three years of records, to ensure at least two years of not 179 
using PPI/H2RA), respectively. 180 
Finally, separate analyses, varying the duration of lags as above, were conducted for 181 
omeprazole and lansoprazole (the most commonly used PPI) and cimetidine and ranitidine 182 
(the most commonly used H2RA). 183 
UK Biobank 184 
Data source  185 
The UK Biobank is a large prospective cohort that recruited approximately 500,000 adults 186 
aged 40-70 across England, Wales and Scotland from 2006 to 201033. At baseline, the 187 
participants completed a touchscreen questionnaire (which captured demographic data, 188 
lifestyle and environmental exposures, and medical history), underwent physical 189 
measurements and provided blood and urine samples. The UK Biobank is linked to cancer 190 
registries from the Health and Social Care Information Centre (England and Wales), or the 191 
National Health Service Central Register (Scotland). The UK Biobank has ethical approval 192 
from the North West Multi-Centre Research Ethics Committee. All participants provided 193 
written informed consent. 194 
Study design 195 
During the UK Biobank cohort follow-up, newly diagnosed gastric cancer cases were 196 
identified based on the International Classification of Diseases (ICD-10) codes (C16), up to 197 
30 September 2014. Cancer cases were further classified by histology on the basis of ICD for 198 
Oncology codes (ICD-O), as adenocarcinoma (ICD-O 8140–8573) or squamous cell 199 
carcinoma (ICD-O 8050–8082). Additionally, gastric cancers were classified by anatomical 200 
site into: gastric cardia cancer (C16.0) and gastric non-cardia cancer (C16.1–16.5). 201 
Individuals with previous cancer (apart from non-melanoma skin cancer) before baseline or 202 
in the year after baseline were excluded (as those cancer cases might have been present at 203 
baseline). We started the follow-up from one year after baseline and ended at the earliest of 204 
gastric cancer diagnosis or censoring due to death, emigration, or 30 September 2014.  205 
Exposure  206 
PPI and H2RA use was self-reported at the baseline using the touch screen questionnaire, 207 
then verified during verbal interview with a UK Biobank nurse.  208 
Covariates 209 
Information on potential risk factors for gastric cancer were retrieved from electronic 210 
touchscreen records, collected at baseline, including smoking status (never, ever and current 211 
smoker), alcohol consumption (never, <1 day per week, 1-2 days per week, 3-4 days per 212 
week, or >4 days per week), BMI (categorized as underweight or normal [<25], overweight 213 
[25-30] or obese [>30]), comorbidities (including GORD, peptic ulcer, oesophagitis, and 214 
diabetes), and deprivation which was retrieved from Townsend score (based on postcode of 215 
usual residence)34. Other medication use (statins and aspirin) at baseline also was ascertained. 216 
Statistical analysis 217 
In UK Biobank, we used Cox regression models (with age as the underlying time scale) to 218 
calculate hazard ratios (HR) and 95% CI for the association between PPI/H2RA and gastric 219 
cancer risk before and after adjustment. All analyses were adjusted for age, sex, deprivation, 220 
BMI, alcohol, smoking, comorbidities at baseline (including diabetes, GORD, oesophagitis, 221 
and peptic ulcer), and statins/aspirin use at baseline. Separate analyses were conducted by 222 
medication subtypes, gastric cancer subtypes (gastric adenocarcinoma, gastric cardia, and 223 
gastric non-cardia).  224 
Sensitivity analyses were conducted stratifying by sex, additionally adjusting for H2RA, 225 
additionally adjusting for year of cohort entry, removing GORD, oesophagitis and peptic 226 
ulcer from the main model (as these could like on the causal pathway), and by repeating the 227 
analyses using lags of two and three years by starting follow-up at two and three years after 228 
baseline, respectively. 229 
 230 
  231 
Results  232 
Primary Care Clinical Informatics Unit database 233 
In PCCIU database, we initially identified 1,129 gastric cancer cases, after dropping 10 cases 234 
without matched controls, this study included 1,119 gastric cancer cases and 5,394 matched 235 
controls, amongst 90% of the cases were matched with five controls. The median duration of 236 
the exposure period was 5.1 (range 2.0 to 13.7) years for cases and controls. Generally, 237 
demographic, lifestyle and healthy characteristics were similar in gastric cancer cases and 238 
controls though a greater proportion of gastric cancer cases were former or current smokers, 239 
see Table 1 and Appendix 1 for comorbidities. 240 
Overall, a greater proportion of gastric cancer cases used PPI compared with controls (29.4% 241 
vs 22.5%; Table 2). Use of PPI was associated with a 45% increase in the risk of gastric 242 
cancer (unadjusted OR=1.45, 95% CI 1.25, 1.68) which was little altered after adjustment for 243 
confounders (fully adjusted OR=1.49, 95% CI 1.24, 1.80), Table 2. The association appeared 244 
slightly more marked for females (fully adjusted OR=1.84, 95% CI 1.38, 2.47) compared 245 
with males (fully adjusted OR=1.26, 95% CI 0.97, 1.62), however there was little evidence of 246 
a difference (P for interaction=0.092). Dose-response analysis by DDD showed that this 247 
association was most marked for short-term use of PPI (183 or less DDD PPI versus no use, 248 
fully adjusted OR=1.84, 95% CI 1.43, 2.38) and was attenuated for longer-term use of PPI 249 
(1096 or more DDD versus no use, fully adjusted OR=1.30, 95% CI 0.91, 1.85). A similar 250 
pattern of results was found when dose-response analysis was examined by increasing 251 
number of prescriptions. There was no evidence of an association between use of high-dose 252 
PPI and gastric cancer risk (fully adjusted OR=1.23, 95% CI 0.76, 1.97). When lags of two or 253 
three years were used (i.e. removing prescriptions in the two or three years before diagnosis) 254 
the overall association was attenuated (fully adjusted OR=1.13, 95% CI 0.91, 1.40, and fully 255 
adjusted OR=1.03, 95% CI 0.80, 1.33, respectively), see Table 2 and Appendix 3 for 256 
graphical presentation. Further analysis of PPI use in specific periods before diagnosis 257 
showed that PPI were much more commonly used in gastric cancer cases compared with 258 
controls in the year before cancer diagnosis (fully adjusted OR=7.04, 95% CI 5.57, 8.61) and 259 
in the period of one to two years before diagnosis (fully adjusted OR=1.51, 95% CI 1.23, 260 
1.84), but not before this time. Moreover, 33.6% of gastric cancer patients newly used PPI in 261 
the year before diagnosis compared with 4.4% of controls (fully adjusted OR=10.98, 95% CI 262 
8.47, 14.23) and this association was slightly more marked in the 55 to 69 age group 263 
(Appendix 2).  264 
Similarly, H2RA use was associated with an increase in the risk of gastric cancer (fully 265 
adjusted OR=1.44, 95% CI 1.16, 1.80; see Table 3). Similar associations were observed in 266 
stratified analysis by sex (fully adjusted OR=1.43, 95% CI 1.05, 1.94 in men and fully 267 
adjusted OR=1.45, 95% CI 1.04, 2.01 in women, respectively). No clear dose-response was 268 
observed as increases in risk were seen even for short-term use (183 or less DDD H2RA 269 
versus never use, adjusted OR=1.40, 95% CI 1.05, 1.85). The H2RA association was slightly 270 
attenuated when removing prescriptions in the two years before diagnosis and largely 271 
attenuated when three years were removed (fully adjusted OR=1.32, 95% CI 1.02, 1.70 and 272 
fully adjusted OR=1.16, 95% CI 0.85, 1.57, respectively). H2RA was more commonly used 273 
and associated with an increased risk of gastric cancer in the period of one year before 274 
diagnosis (fully adjusted OR=3.07, 95% CI 2.37, 3.98), one to two years before diagnosis 275 
(fully adjusted OR=1.87, 95% CI 1.40, 2.50), and two to three years before diagnosis (fully 276 
adjusted OR=1.55, 95% CI 1.11, 2.16), but not before this time. Overall, 7.9% of gastric 277 
cancer patients newly used H2RA in the year before diagnosis compared with 1.1% of 278 
controls (fully adjusted OR=9.87, 95% CI 6.04, 16.15) and this association was more marked 279 
in the group aged younger than 55 years (Appendix 2).   280 
PPI and H2RA associations were generally similar by medication subtype, after additional 281 
adjustment for each other, when no adjusting for peptic ulcer disease and oesophagitis, and 282 
when adjusting for lifestyle factors using multiple imputation, Tables 2 and 3. Null 283 
associations were observed when using an active comparator analysis (fully adjusted 284 
OR=1.34, 95% CI 0.85, 2.09 in PPI users when using only H2RA users as an active 285 
comparator, and fully adjusted OR=0.86, 95% CI 0.60, 1.24 in H2RA users when using only 286 
PPI users as an active comparator, respectively), see Tables 2 and 3. 287 
UK Biobank 288 
There were 502,543 participants in the UK Biobank cohort, 26,869 were removed because 289 
they developed cancer before the first year after baseline and 3,898 were removed because 290 
they died within the first year, leaving 471,779 in final cohort for analysis of whom 250 were 291 
diagnosed with gastric cancer during the median follow-up of 4.6 years (interquartile range: 292 
3.9–5.3 years). Those who were diagnosed with gastric cancer were more likely be older, 293 
male, from deprived areas, smoke, be overweight or obese, have comorbidities, and use 294 
statins and aspirin (Table 1).  295 
There was an increase in gastric cancer risk with PPI use (unadjusted HR=1.53, 95% CI 1.10, 296 
2.12) but this risk was attenuated after adjustment for confounders (adjusted HR=1.28, 95% 297 
CI 0.86, 1.90; see Table 4). These associations were attenuated when using a lag of two years 298 
by starting follow-up at two years after baseline (unadjusted HR=1.28, 95% CI 0.86, 1.89 and 299 
adjusted HR=1.15, 95% CI 0.73, 1.82).  300 
The association for PPI use appeared more marked for non-cardia gastric cancer compared 301 
with cardia gastric cancer before adjustment (unadjusted HR=1.93, 95% CI 1.06, 3.50 and 302 
HR=1.26, 95% CI 0.72, 2.18, respectively) but not after adjustment (adjusted HR=1.44, 95% 303 
CI 0.68, 3.06 and HR=0.81, 95% CI 0.40, 1.64, respectively). The association was similar for 304 
gastric adenocarcinoma, by medication subtype, after additional adjustment for H2RA and 305 
after additional adjustment for year of cohort entry, but slightly less marked for male, whilst 306 
more marked when not adjusting for GORD, oesophagitis and peptic ulcer, see Table 4.   307 
There was no evidence of an increase in gastric cancer risk with H2RA use (adjusted 308 
HR=0.49, 95% CI 0.16, 1.56), but the numbers of H2RA use was small precluding further 309 
analysis.   310 
 311 
  312 
Discussion 313 
In both the PCCIU case-control study and UK Biobank cohort study we observed little 314 
consistent evidence of an increased risk of gastric cancer with PPI use. Although using a one 315 
year lag there was an association between PPI and gastric cancer, this association did not 316 
follow an exposure response (for instance those using for the shortest period had the highest 317 
risk) and was attenuated with longer lags suggesting the role of reverse causation (for 318 
instance, associations weakened when prescriptions in the two year period prior to diagnosis 319 
were removed in PCCIU and incident gastric cancers within two years after baseline were 320 
removed in UK Biobank). A similar pattern of association was observed in PCCIU for H2RA 321 
but there was no association between H2RA use and gastric cancer in UK Biobank. 322 
Our PPI findings contrast with the most recent meta-analysis, in which a marked increase in 323 
gastric cancer risk with prolonged PPI use was observed with a pooled OR of 2.5 in seven 324 
observational studies9. However there was marked heterogeneity in the observed associations 325 
with odds ratios varying from 1.5 to 24.1 across the seven studies and an earlier meta-326 
analysis observed a less marked association for any PPI use (pooled OR of 1.4)10. Our 327 
findings are more consistent with this earlier meta-analysis. In our study, the association 328 
between PPI use and gastric cancer risk was sensitive to the lag time duration but the optimal 329 
biologically relevant lag time is unclear. In our main analysis we used a lag time of one year 330 
which assumes that PPI would take at least one year to induce a gastric cancer and for it to 331 
develop to the point of detection. Should this process take longer then extended lag times 332 
would be more appropriate. Previous studies have also observed that the association between 333 
PPI use and gastric cancer risk is reduced with longer lag times. For instance, a Canadian 334 
study observed a marked association between PPI and gastric cancer (OR of 2.9) but this was 335 
attenuated with a two years lag time (OR of 1.2)35. Also a Swedish cohort study observed a 336 
marked association (standardised incidence ratios [SIR] of 3.4) which was attenuated after 337 
excluding cancers in the year after medication started (SIR=1.6)11. Similarly, a UK study 338 
observed an association between PPI and gastric cancer risk only in current users who used in 339 
the year before diagnosis36. Any difference in our findings and the previous meta-analyses 340 
could reflect ethnic differences, as two studies were based upon Asian populations and 341 
investigated PPI in the context of H. pylori eradication13,37, or confounding as some studies 342 
had limited confounders such as alcohol11.  343 
Of relevance, two systematic reviews of RCTs of PPI found no evidence that PPI could cause 344 
or accelerate the development of the premalignant gastric lesions, atrophic gastritis and 345 
intestinal metaplasia, but the numbers of included events were small38,39.   346 
Our H2RA findings are similar to a meta-analysis which observed a pooled OR of 1.4 in ten 347 
observational studies10. The less marked association in our study could reflect better 348 
adjustment for confounders in our study or the inclusion of low quality observational studies 349 
in that review both of which were shown to influence the pooled OR with more recent studies 350 
and studies of higher quality observing less marked estimates.  351 
In our study around one third of gastric cancer patients newly used PPI in the year before 352 
cancer diagnosis, similar but lower than seen in the latest Swedish study40. This should raise 353 
the question in the mind of the clinician prescribing a first course of PPI: could these 354 
dyspepsia symptoms be a signal of early gastric cancer41? Recommending further action on 355 
the basis of new use of PPI alone however does not appear to be warranted because PPI is 356 
very widely prescribed and this approach would only capture a third of gastric cancer 357 
patients. However, since early detection is a key determinant of survival in gastric cancer, it 358 
is possible that future research could investigate new use of acid suppression therapy along 359 
with other factors to identify those at highest risk. 360 
The main strength of our study is to utilize high quality population-based data from two 361 
independent sources. In PCCIU, medication use was determined from GP prescription 362 
records avoiding recall bias and providing detailed information on the timing, dose and 363 
quantities prescribed. In UK Biobank, cancer outcome was determined from cancer registry 364 
records, providing verified information on tumour histology and location. Additionally, in 365 
both analyses, we were able to adjust for a wide range of covariates including many of the 366 
main risk factors for gastric cancer such as age, sex, deprivation, smoking, BMI, alcohol 367 
consumption, relevant comorbidities (including peptic ulcer, oesophagitis in PCCIU, and 368 
GORD, peptic ulcer and oesophagitis in UK Biobank) and medication use (including statins 369 
and aspirin).  370 
Several limitations of our study must be acknowledged. First, in UK Biobank medication use 371 
was based upon self-report, and even though this was verified by nurses, we could not obtain 372 
the dose or the frequency of medication use. Second, UK Biobank has been shown to be 373 
healthier than the general population42, however aetiological findings from UK Biobank 374 
appear to be generalisable to the UK population43. Although some inaccuracy in identifying 375 
gastric cancer in GP records from PCCIU is inevitable, in general the recording of cancer 376 
outcomes within UK GP records has been shown to be fairly accurate44. Another potential 377 
limitation was confounding by indication as despite having a wide range of comorbidities we 378 
were not able to adjust for H. pylori, an important risk factor for gastric cancer45. 379 
To conclude, we found some evidence of associations between PPI and H2RA use and gastric 380 
cancer risk in a large population-based case-control study and a cohort study. These 381 
associations were sensitive to the duration of lag time used in the analysis. Our results 382 
revealed a marked increase in the prescription of acid suppression medications immediately 383 
before gastric cancer diagnosis suggesting the role of reverse causation.  384 
Acknowledgements 385 
Access to UK Biobank data was approved and facilitated by UK Biobank (application 386 
number: 34374).  Access to Primary Care Clinical Informatics Unit (PCCIU) data was 387 
approved and facilitated by the PCCIU Research team, University of Aberdeen. Access to the 388 
UK Biobank was funded by a Cancer Research UK Population Research Postdoctoral 389 
Fellowship awarded to ÚCMcM. 390 
 391 
Author contributions 392 
Study concept and design: Lee AJ, Cardwell CR, Iversen L and Murchie P. Data acquisition: 393 
Lee AJ, Cardwell CR, Iversen L, Murchie P and McMenamin UC. Funding for various 394 
aspects of study: Lee AJ, Cardwell CR, Iversen L, Murchie P, Liu P and McMenamin UC. 395 
Statistical analysis: Cardwell CR and Liu P. Data interpretation: Cardwell CR, Liu P, 396 
Johnston BT, Iversen L, Murchie P, Vissers PAJ and McMenamin UC. Study supervision: 397 
Cardwell CR. Critical review of the article for important intellectual content: Cardwell CR, 398 
Murchie P, Johnston BT, Iversen L, Vissers PAJ. Article writing: Cardwell CR and Liu P. 399 
Final approval: all authors. 400 
 401 
Additional information 402 
Ethics approval and consent to participate 403 
Ethical approval for the PCCIU data was supplied by the Queen’s University Belfast, School 404 
of Medicine, Dentistry and Biomedical Sciences Research Ethics Committee (reference 405 
number: 15.43).  The UK Biobank has ethical approval from the North West Multi-Centre 406 
Research Ethics Committee. All UK Biobank participants provided written informed consent. 407 
The study was performed in accordance with the Declaration of Helsinki.    408 
 409 
Consent for publication:  410 
Not applicable. 411 
 412 
Data availability: 413 
The UK Biobank data (https://www.ukbiobank.ac.uk/) and PCCIU data 414 
(https://www.abdn.ac.uk/iahs/research/primary-care/pcciur/) are available, following the 415 
access procedures, for researchers to access to conduct health related research in the public 416 
interest. 417 
 418 
Competing interests: 419 
All authors have no competing interests to declare. 420 
 421 
Funding: 422 
Access to the UK Biobank was funded by a Cancer Research UK Population Research 423 
Postdoctoral Fellowship awarded to ÚCMcM. Liu P was supported by a joint scholarship 424 
from Queen's University Belfast and the Chinese Scholarship Council (201708060458).425 
Reference  426 
1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global 427 
cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide 428 
for 36 cancers in 185 countries. CA. Cancer J. Clin. 68, 394–424 (2018).  429 
2. Arnold, R. Safety of proton pump inhibitors--an overview. Aliment. Pharmacol. Ther. 430 
8, 65–70 (1994). 431 
3. Dacha, S., Razvi, M., Massaad, J., Cai, Q. & Wehbi, M. Hypergastrinemia. 432 
Gastroenterol. Rep. 3, 201–8 (2015). 433 
4. Bordi, C., D’Adda, T., Azzoni, C., Pilato, F. P. & Caruana, P. Hypergastrinemia and 434 
gastric enterochromaffin-like cells. Am. J. Surg. Pathol. 19 Suppl 1, S8-19 (1995). 435 
5. Sanduleanu, S., Jonkers, D., De Bruine, A., Hameeteman, W. & Stockbrugger, R. W. 436 
Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential 437 
findings in gastric juice and gastric mucosa. Aliment. Pharmacol. Ther. 15, 379–388 438 
(2001). 439 
6. Corsonello, A., Lattanzio, F., Bustacchini, S., Garasto, S., Cozza, A., Schepisi, R. et al. 440 
Adverse Events of Proton Pump Inhibitors: Potential Mechanisms. Curr. Drug Metab. 441 
19, 142–154 (2018). 442 
7. Tran-Duy, A., Spaetgens, B. & Hoes, A. Use of proton pump inhibitors and risks of 443 
fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin 444 
Gastroenterol Hepatol 14, 1706–19 (2016). 445 
8. Cheung, K. S. & Leung, W. K. Long-term use of proton-pump inhibitors and risk of 446 
gastric cancer: a review of the current evidence. Therap. Adv. Gastroenterol. 12, 447 
175628481983451 (2019). 448 
9. Jiang, K., Jiang, X., Wen, Y., Liao, L. & Liu, F. Relationship between long‐term use of 449 
proton pump inhibitors and risk of gastric cancer: A systematic analysis. J. 450 
Gastroenterol. Hepatol. jgh.14759 (2019). 451 
10. Ahn, J. S., Eom, C.-S., Jeon, C. Y. & Park, S. M. Acid suppressive drugs and gastric 452 
cancer: A meta-analysis of observational studies. World J Gastroenterol 19, 2560–453 
2568 (2013). 454 
11. Brusselaers, N., Wahlin, K., Engstrand, L. & Lagergren, J. Maintenance therapy with 455 
proton pump inhibitors and risk of gastric cancer: a nationwide population-based 456 
cohort study in Sweden. BMJ Open 7, e017739 (2017). 457 
12. Crane, S. J., Locke, G. R., Harmsen, W. S,, Diehl, N. N., Zinsmeister, A. R., Melton, 458 
L. J. et al. Subsite-specific risk factors for esophageal and gastric adenocarcinoma. 459 
Am. J. Gastroenterol. 102, 1596–602 (2007). 460 
13. Niikura, R. Hayakawa, Y., Hirata, Y., Yamada, A., Fujishiro, M. & Koike, K. Long-461 
term proton pump inhibitor use is a risk factor of gastric cancer after treatment for 462 
Helicobacter pylori: A retrospective cohort analysis. Gut vol. 67 (2018). 463 
14. Pottegård, A., Friis, S., Stürmer, T., Hallas, J. & Bahmanyar, S. Considerations for 464 
Pharmacoepidemiological Studies of Drug-Cancer Associations. Basic Clin. 465 
Pharmacol. Toxicol. 122, 451–459 (2018). 466 
15. Correa, P. & Piazuelo, M. B. The gastric precancerous cascade. J. Dig. Dis. 13, 2–9 467 
(2012). 468 
16. Griffin, S. M. & Raimes, S. A. Proton pump inhibitors may mask early gastric cancer. 469 
Br. Med. J. 317, 1606–1607 (1998). 470 
17. Corley, D. A. Safety and Complications of Long-Term Proton Pump Inhibitor 471 
Therapy: Getting Closer to the Truth. Gastroenterology. 157, 604–607, (2019). 472 
18. University of Aberdeen. Primary Care Clinical Informatics Unit Research | The 473 
Institute of Applied Health Sciences | The University of Aberdeen. 474 
https://www.abdn.ac.uk/iahs/research/primary-care/pcciur/index.php. 475 
19. NHS, N. B. What are the Read Codes? Health Libr. Rev. 11, 177–182 (1994). 476 
20. Arfè, A. & Corrao, G. The lag-time approach improved drug–outcome association 477 
estimates in presence of protopathic bias. J. Clin. Epidemiol. 78, 101–107 (2016). 478 
21. Joint Formulary Committee (Great Britain), British Medical Association. & 479 
Pharmaceutical Society of Great Britain. BNF 77, March 2019. (2019). 480 
22. Nahler, G. defined daily dose (DDD). in Dictionary of Pharmaceutical Medicine 49–481 
49 (Springer Vienna, 2009).  482 
23. World Health Organisation. World Health Organisation Collaborating Centre for Drug 483 
Statistics and Methodology. 484 
https://www.whocc.no/ddd/definition_and_general_considera/. 485 
24. Overview | Gastro-oesophageal reflux disease and dyspepsia in adults: investigation 486 
and management | Guidance | NICE. 487 
25. Donnelly R. Scottish Index of Multiple Deprivation 2009: General Report. (Edinburgh, 488 
UK: Office of the Chief Statistician (The Scottish Government), 2009). 489 
26. Wang, W. H. Non-steroidal Anti-inflammatory Drug Use and the Risk of Gastric 490 
Cancer: A Systematic Review and Meta-analysis. CancerSpectrum Knowl. Environ. 491 
95, 1784–91 (2003). 492 
27. Wang, W., Jin, G., Chu, P., Li, H. & Ma, Z. Effect of statins on gastric cancer 493 
incidence: A meta-Analysis of case control studies. J. Cancer Res. Ther. 10, 859–865 494 
(2015). 495 
28. Kim, Y. I., Kim, S. Y., Kim, J. H., Lee, J. H., Kim, Y. W., Ryu, K. W. et al. Long-term 496 
low-dose aspirin use reduces gastric cancer incidence: A nationwide cohort study. 497 
Cancer Res. Treat. 48, 798–805 (2016). 498 
29. Jankowski, J. A. Z., de Caestecker, J., Love, S. B., Reilly, G., Watson, P., Sanders, S.  499 
et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised 500 
factorial trial. Lancet (London, England) 392, 400–408 (2018). 501 
30. White, I. R., Royston, P. & Wood, A. M. Multiple imputation using chained equations: 502 
Issues and guidance for practice. Stat. Med. 30, 377–399 (2011). 503 
31. Sterne, J. A. C. et al. Multiple imputation for missing data in epidemiological and 504 
clinical research: potential and pitfalls. BMJ. 338, b2393–b2393 (2009). 505 
32. Tamim, H., Monfared, A. A. T. & LeLorier, J. Application of lag-time into exposure 506 
definitions to control for protopathic bias. Pharmacoepidemiol. Drug Saf. 16, 250–258 507 
(2007). 508 
33. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P. et al. UK Biobank: An Open 509 
Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of 510 
Middle and Old Age. 12, e1001779 (2015). 511 
34. Townsend, P. Deprivation. J. Soc. Policy 16, 125–146 (1987). 512 
35. Tamim, H., Duranceau, A., Chen, L. Q. & LeLorier, J. Association between use of 513 
acid-suppressive drugs and risk of gastric cancer: A nested case-control study. Drug 514 
Saf. 31, 675–684 (2008). 515 
36. García Rodríguez, L. A., Lagergren, J. & Lindblad, M. Gastric acid suppression and 516 
risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. 517 
Gut 55, 1538–44 (2006). 518 
37. Cheung, K. S., Chan, E. W., Wong, A. Y. S., Chen, L., Wong, I. C. K., & Leung W. K. 519 
Long-term proton pump inhibitors and risk of gastric cancer development after 520 
treatment for Helicobacter pylori: a population-based study. Gut 67, 28–35 (2018). 521 
38. Song, H., Zhu, J. & Lu, D. Long-term proton pump inhibitor (PPI) use and the 522 
development of gastric pre-malignant lesions. Cochrane Database Syst. Rev. 12, 523 
CD010623 (2014). 524 
39. Eslami, L. & Nasseri-Moghaddam, S. Meta-analyses: does long-term PPI use increase 525 
the risk of gastric premalignant lesions? Arch. Iran. Med. 16, 449–58 (2013). 526 
40. Brusselaers, N., Lagergren, J. & Engstrand, L. Duration of use of proton pump 527 
inhibitors and the risk of gastric and oesophageal cancer. Cancer Epidemiol. 62, 528 
101585 (2019). 529 





42. Fry, A., Littlejohns, T. .J, Sudlow, C., Doherty, N., Adamska, L., Sprosen, T. et al. 535 
Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank 536 
Participants With Those of the General Population. Am. J. Epidemiol. 186, 1026–1034 537 
(2017). 538 
43. Batty, G. D., Gale, C., Kivimaki, M., Deary, I. & Bell, S. Generalisability of results 539 
from UK Biobank: comparison with a pooling of 18 cohort studies. medRxiv. 540 
19004705 (2019). 541 
44. Dregan, A., Moller, H., Murray-Thomas, T. & Gulliford, M. C. Validity of cancer 542 
diagnosis in a primary care database compared with linked cancer registrations in 543 
England. Population-based cohort study. Cancer Epidemiol. 36, 425–429 (2012). 544 
45. Plummer, M., de Martel, C., Vignat, J., Ferlay, J., Bray, F. &  Franceschi, S. Global 545 
burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob. 546 
Heal. 4, e609–e616 (2016). 547 
 548 
Table 1. Characteristics of gastric cancer cases and controls in PCCIU database and UK Biobank. 
 PCCIU  UK Biobank 
 Cases, n(%) Controls, n (%)  Gastric cancer, 
n (%) 
No gastric cancer, 
n (%) 
Count  1119 (17.3) 5394 (82.8)  250 471529 
      






   
      
Year of diagnosis       
  1996-1999 68 (6.1) 332 (6.2)    
  2000-2003 330 (29.5) 1609 (29.8)    
  2004-2007 494 (44.1) 2359 (43.7)  1 (0.4)  
  2008-2011 227 (20.3) 1094 (20.3)  99 (39.6)  
  2012-2015    150 (60.0)  
      
Age at index/baseline1      
   0-59 165 (14.8) 818 (15.2)  70 (28.0) 273444 (58.0) 
  60-69 292 (26.1) 1450 (26.9)  175 (70.0) 195959 (41.6) 
  70+ 662 (59.2) 3126 (57.9)  5 (2.0) 2126 (0.5) 
      
Male  639 (57.1) 3082 (57.1)  182 (72.8) 217146 (46.1) 
      
Deprivation       
  1 (least deprived) 133 (11.9) 635 (11.9)  41 (16.4) 94422 (20.0) 
  2 182 (16.3) 866 (16.0)  40 (16.0) 94009 (19.9) 
  3 242 (21.6) 1167 (21.6)  49 (19.6) 93929 (19.9) 
  4 284 (25.4) 1378 (25.5)  55 (22.0) 94383 (20.0) 
  5 (most deprived) 268 (23.9) 1300 (24.1)  64 (25.6) 94194 (20.0) 
  Missing  10 (0.9) 48 (0.9)  1 (0.4) 592 (0.1) 
      
Smoking status2      
  Never 387 (34.6) 2052 (38.0)  99 (39.6) 257994 (54.7) 
  Former 320 (28.6) 1414 (26.2)  106 (42.4) 160790 (34.1) 
  Current  249 (22.2) 1009 (18.7)  41 (16.4) 50005 (10.6) 
  Missing  163 (14.6) 919 (17.0)  4 (1.6) 2740 (0.6) 
      
Selected comorbidities      
  GORD     16 (6.4) 19582 (4.2) 
  Peptic ulcer  15 (1.3) 75 (1.4)  7 (2.8) 5724 (1.2) 
  Diabetes  54 (4.8) 222 (4.1)  22 (8.8) 23821 (5.1) 
  Oesophagitis 7 (0.6) 44 (0.8)  4 (1.6) 1361 (0.3) 
        
Other drug use       
  Statins 265 (23.7) 1248 (23.1)  68 (27.2) 76473 (16.2) 
  Aspirin  358 (32.0) 1610 (29.9)  72 (28.8) 64717 (13.7) 
      
BMI      
  Normal/underweight       61 (24.4) 154912 (32.9) 
  Overweight    119 (47.6) 199202 (42.2) 
  Obese 164 (14.7) 1060 (19.7)  70 (28.0) 114501 (24.3) 
  Missing/not obese 955 (85.3) 4334 (80.4)    
  Missing    0 2914 (0.6) 
      
Alcohol consumption2       
  Never  237 (21.2) 969 (18.0)  27 (10.8) 37865 (8.0) 
  <1 day per wk    62 (24.8) 106482 (22.6) 
  1-2 days per wk    58 (23.2) 121461 (25.8) 
  3-4 days per wk    50 (20.0) 108892 (23.1) 
  >4 days per wk    51 (20.4) 95401 (20.2) 
  Low 529 (47.3) 2660 (49.3)    
  High 42 (3.7) 184 (3.4)    
  Missing  311 (27.8) 1581 (29.3)  2 (0.8) 1428 (0.3) 
1 Age at index date in PCCIU database and age at baseline in UK Biobank. 
2 Smoking status and alcohol consumption based upon Read Codes in PCCIU database and questionnaire in UK Biobank. 
 
Table 2. The association between PPI use and the risk of gastric cancer in PCCIU database. 
   Unadjusted Adjusted1 Fully adjusted2 
 Case, n(%) Control, n(%) OR (95%CI) OR (95%CI) OR (95%CI) 
PPI main analysis (removing 1 year before index)      
  PPI user vs. non-user 329/1119 (29.4) 1213/5394 (22.5) 1.45 (1.25, 1.68) 1.48 (1.26, 1.73) 1.49 (1.24, 1.80) 
      
  Male only  167/639 (26.1) 668/3082 (21.7) 1.29 (1.05, 1.58) 1.30 (1.05, 1.61) 1.26 (0.97, 1.62) 
  Female only 162/180 (33.8) 545/2312 (23.6) 1.66 (1.33, 2.06) 1.74 (1.38, 2.19) 1.84 (1.38, 2.47) 
      
  High-dose PPI user vs. non-user  33/1119 (3.0) 109/5394 (2.0) 1.40 (0.94, 2.10) 1.40 (0.93, 2.12) 1.23 (0.76, 1.97) 
      
Dose-response analysis (removing 1 year before index) 
  1-183 DDDs  vs. non-user 141/1119 (12.6) 441/5394 (8.2) 1.74 (1.41, 2.14) 1.77 (1.43, 2.19) 1.84 (1.43, 2.38) 
  184-365 DDDs vs. non-user 43/1119 (3.8) 163/5394 (3.0) 1.41 (1.00, 1.99) 1.48 (1.04, 2.09) 1.49 (0.97, 2.28) 
  366-1095 DDDs vs. non-user 81/1119 (7.2) 352/5394 (6.5) 1.21 (0.94, 1.56) 1.23 (0.94, 1.59) 1.20 (0.89, 1.64) 
  ≥1096 DDDs vs. non-user 64/1119 (5.7) 257/5394 (4.8) 1.32 (0.98, 1.77) 1.31 (0.97, 1.77) 1.30 (0.91, 1.85) 
  P-value for the trend    0.003 0.004 0.026 
      
  1-12 prescriptions vs. non-user 153/1119 (13.7) 482/5394 (13.7) 1.71 (1.40, 2.10) 1.74 (1.42, 2.14) 1.85 (1.44, 2.37) 
  12-24 prescriptions vs. non-user 44/1119 (3.9) 167/5394 (3.1) 1.42 (1.01, 2.00) 1.46 (1.04, 2.07) 1.39 (0.91, 2.13) 
  24-36 prescriptions vs. non-user 90/1119 (8.0) 366/5394 (6.8) 1.31 (1.02, 1.68) 1.33 (1.04, 1.72) 1.35 (1.00, 1.82) 
  ≥36 prescriptions vs. non-user 42/1119 (3.7) 198/5394 (3.7) 1.07 (0.75, 1.53) 1.06 (0.74, 1.52) 0.97 (0.64, 1.47) 
  P-value for the trend   0.008 0.010 0.073 
      
PPI user vs. non-user when removing prescriptions in specific duration 
  Removing 2 years before index 212/862 (24.6) 878/4126 (21.3) 1.20 (1.00, 1.43) 1.19 (0.99, 1.43) 1.13 (0.91, 1.40) 
  Removing 3 years before index 137/644 (21.3) 620/3062  (20.3) 1.04 (0.84, 1.28) 1.04 (0.83, 1.29) 1.03 (0.80, 1.33) 
  Removing 4 years before index 87/474 (18.3) 421/2235 (18.8) 0.93 (0.71, 1.21) 0.92 (0.70, 1.21) 0.89 (0.65, 1.22) 
  Removing 5 years before index 55/345 (15.9) 267/1611 (16.6) 0.90 (0.65, 1.25) 0.90 (0.64, 1.26) 0.82 (0.55, 1.22) 
      
PPI user in specific time periods before index date/cancer diagnosis date 
   0-1 y before index3 664/1119 (59.3) 1088/5394 (20.2) 6.32 (5.44, 7.33)  6.79 (5.82, 7.91) 7.04 (5.75, 8.61) 
   1-2 y before index4 259/1119 (23.2) 926/5394 (17.2) 1.45 (1.23, 1.70) 1.47 (1.25, 1.74) 1.51 (1.23, 1.84) 
   2-3 y before index5 165/862 (19.1) 670/4126 (16.2) 1.20 (0.99, 1.46) 1.20 (0.98, 1.47) 1.15 (0.90, 1.46) 
   3-4 y before index6 107/644 (16.6) 481/3062 (15.7) 1.04 (0.82, 1.31) 1.02 (0.81, 1.30) 1.00 (0.76, 1.33) 
   4-5 y before index7 68/474 (14.4) 329/2235 (14.7) 0.93 (0.70, 1.24) 0.92 (0.69, 1.23) 0.96 (0.68, 1.35) 
      
PPI new user vs. PPI non-new-user8 376/1119 (33.6) 235/5394 (4.4) 10.93 (9.01,13.25) 11.11 (9.14, 13.51) 10.98 (8.47, 14.23) 
      
Omeprazole user vs. non-user      
  Removing 1 years before index 201/1119 (18.0) 774/5394  (14.4) 1.30 (1.09, 1.55) 1.29 (1.07, 1.54) 1.21 (0.97, 1.50) 
  Removing 2 years before index 123/862 (14.3) 548/4126 (13.3) 1.06 (0.85, 1.32) 1.03 (0.82, 1.29) 0.92 (0.70, 1.20) 
  Removing 3 years before index 78/644 (12.1) 373/3062 (12.2) 0.95 (0.73, 1.24) 0.95 (0.72, 1.25) 0.89 (0.65, 1.23) 
Lansoprazole user vs. non-user      
  Removing 1 years before index 169/1119 (15.1) 610/5394 (11.3) 1.40 (1.16, 1.69) 1.42 (1.17, 1.73) 1.49 (1.18, 1.88) 
  Removing 2 years before index 114/862 (13.2) 447/4126 (10.8) 1.24 (0.99, 1.56) 1.24 (0.99, 1.57) 1.27 (0.97, 1.66) 
  Removing 3 years before index 75/644 (11.7) 319/3062 (10.4) 1.11 (0.85, 1.46) 1.12 (0.84, 1.48) 1.17 (0.85, 1.62) 
      
Sensitivity analysis (PPI user versus non-user)     
  Additionally adjusted for H2RA9 329/1119 (29.4) 1213/5394 (22.5) 1.45 (1.25, 1.68) 1.41 (1.20, 1.65) 1.43 (1.18, 1.73) 
  PPI user vs. H2RA user10 329/431 (76.3) 1213/1604 (75.6) 1.18 (0.85, 1.65) 1.24 (0.88, 1.75) 1.34 (0.85, 2.09) 
  Adjusted for lifestyle using multiple 
imputation11 
329/1119 (29.4) 1213/5394 (22.5) 1.45 (1.25, 1.68) 1.48 (1.26, 1.73) 1.47 (1.26, 1.72) 
  Additionally not adjusted for peptic 
ulcer and oesophagitis12 
329/1119 (29.4) 1213/5394 (22.5) 1.45 (1.25, 1.68) 1.45 (1.25, 1.69) 1.44 (1.20, 1.74) 
1 Study matched on age, sex and general practice and model contains obesity, comorbidities in exposure period (including diabetes, coronary heart 
disease, myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, cerebrovascular accident, chronic obstructive 
pulmonary disease, mental illness, liver disease, peptic ulcer, oesophagitis) and other medication use in exposure period (statins, aspirin). 
2 Additionally adjusted for alcohol and smoking. 
3 Medication use in the year prior to diagnosis/index date restricted to individuals with at least 3 years of records. 
4 Medication use in the year from 2 years to 1 year prior to diagnosis/index date restricted to individuals with at least 3 years of records. 
5 Medication use in the year from 3 years to 2 years prior to diagnosis/index date restricted to individuals with at least 4 years of records. 
6 Medication use in the year from 4 years to 3 years prior to diagnosis/index date restricted to individuals with at least 5 years of records. 
7 Medication use in the year from 5 years to 4 years prior to diagnosis/index date restricted to individuals with at least 6 years of records. 
8 Proportion of cases and controls who used PPI in the year before diagnosis and who had not previously used PPI.  
9 Additionally adjusted for H2RA. 
10 Using only H2RA users as an active comparator. 
11 Using multiple imputation to adjust for alcohol and smoking. 
12 Removing the peptic ulcer and oesophagitis adjustment from main model. 
 
Table 3. The association between H2RA use and the risk of gastric cancer in PCCIU database. 
   Unadjusted Adjusted1 Fully adjusted2 
 Case, n(%) Control, n(%) OR (95%CI) OR (95%CI) OR (95%CI) 
H2RA main analysis (removing 1 year before index)      
  H2RA user vs. non-user 199/1119 (17.8) 689/5394 (12.8) 1.49 (1.25, 1.77) 1.49 (1.24, 1.78) 1.44 (1.16, 1.80) 
      
  Male only  100/639 (15.6) 356/3082 (11.6) 1.42 (1.11, 1.82) 1.41 (1.10, 1.81) 1.43 (1.05, 1.94) 
  Female only  99/480 (20.6) 333/2312 (14.4) 1.56 (1.21, 2.01) 1.57 (1.21, 2.04) 1.45 (1.04, 2.01) 
      
Dose-response analysis (removing 1 year before index) 
  1-183 DDDs vs. non-user 107/1119 (9.6) 370/5394 (6.9) 1.49 (1.18, 1.87) 1.49 (1.18, 1.88) 1.40 (1.05, 1.85) 
  184-365 DDDs vs. non-user 22/1119 (2.0) 76/5394 (1.4) 1.50 (0.93, 2.41) 1.49 (0.92, 2.40) 1.42 (0.77, 2.60) 
  366-1095 DDDs vs. non-user 51/1119 (4.6) 172/5394 (3.2) 1.52 (1.10, 2.10) 1.51 (1.09, 2.10) 1.50 (0.99, 2.29) 
  ≥1096 DDDs vs. non-user 19/1119 (1.7) 71/5394 (1.3) 1.38 (0.82, 2.33) 1.37 (0.81, 2.32) 1.62 (0.86, 3.05) 
  P-value for the trend   <0.001 <0.001 0.003 
      
  1-12 prescriptions vs. non-user 105/1119 (9.4) 375/5394 (6.9) 1.44 (1.14, 1.81) 1.44 (1.14, 1.82) 1.38 (1.04, 1.83) 
  12-24 prescriptions vs. non-user 34/1119 (3.0) 101/5394 (1.8) 1.72 (1.16, 2.56) 1.71 (1.15, 2.55) 1.54 (0.93, 2.54) 
  24-36 prescriptions vs. non-user 46/1119 (4.1) 163/5394 (3.0) 1.46 (1.04, 2.05) 1.45 (1.03, 2.05) 1.58 (1.03, 2.42) 
  ≥36 prescriptions vs. non-user 14/1119 (1.3) 50/5394 (0.9) 1.44 (0.79, 2.63) 1.44 (0.79, 2.64) 1.34 (0.62, 2.90) 
  P-value for the trend   <0.001 <0.001 0.003 
      
H2RA user vs. non-user when removing prescriptions in specific duration 
  Removing 2 years before index 137/862 (15.9) 518/4126 (12.6) 1.32 (1.07, 1.63) 1.30 (1.05, 1.61) 1.32 (1.02, 1.70) 
  Removing 3 years before index 93/644 (14.4) 386/3062 (12.6) 1.16 (0.90, 1.50) 1.15 (0.89, 1.48) 1.16 (0.85, 1.57) 
  Removing 4 years before index 63/474 (13.3) 284/2235 (12.7) 1.03 (0.76, 1.39) 1.01 (0.74, 1.37) 1.06 (0.74, 1.52) 
  Removing 5 years before index 44/345 (12.8) 199/1611 (12.4) 1.00 (0.70, 1.43) 0.99 (0.69, 1.43) 1.13 (0.74, 1.72) 
      
H2RA user in specific time periods before index date/cancer diagnosis date  
   0-1 y before index3 178/1119 (15.9) 323/5394 (6.0) 3.05 (2.49, 3.72) 3.04 (2.48, 3.72) 3.07 (2.37, 3.98) 
   1-2 y before index4 114/1119 (10.2) 329/5394 (6.1) 1.77 (1.42, 2.22) 1.78 (1.41, 2.23) 1.87 (1.40, 2.50) 
   2-3 y before index5 77/862 (8.9) 263/4126 (6.4) 1.46 (1.12, 1.91) 1.45 (1.11, 1.91) 1.55 (1.11, 2.16) 
   3-4 y before index6 53/644 (8.4) 196/3062 (6.4) 1.32 (0.96, 1.83) 1.33 (0.96, 1.85) 1.26 (0.85, 1.87) 
   4-5 y before index7 38/474 (8.0) 136/2235 (6.1) 1.35 (0.92, 1.98) 1.34 (0.91, 1.97) 1.29 (0.81, 2.05) 
      
H2RA new user vs. H2RA non-new-user8 89/1119 (7.9) 58/5394 (1.1) 8.11 (5.75, 11.43) 8.26 (5.85, 11.68) 9.87 (6.04, 16.15) 
      
Cimetidine user vs. non-user      
  Removing 1 years before index 85/1119 (7.6) 254/5394 (4.7) 1.68 (1.30, 2.17) 1.66 (1.28, 2.15) 1.43 (1.02, 2.01) 
  Removing 2 years before index 62/862 (7.2) 193/4126 (4.7) 1.59 (1.18, 2.15) 1.55 (1.14, 2.10) 1.31 (0.90, 1.93) 
  Removing 3 years before index 39/644 (6.1) 148/3062 (4.8) 1.27 (0.88, 1.83) 1.23 (0.85, 1.79) 1.10 (0.70, 1.75) 
Ranitidine user vs. non-user      
  Removing 1 years before index 128/1119 (11.4) 459/5394 (8.5) 1.39 (1.12, 1.71) 1.10 (0.94, 1.29) 1.42 (1.10, 1.85) 
  Removing 2 years before index 78/862 (9.1) 341/4126 (8.3) 1.09 (0.84, 1.42) 1.09 (0.84, 1.43) 1.22 (0.89, 1.67) 
  Removing 3 years before index 57/644 (8.9) 255/3062 (8.3) 1.05 (0.77, 1.43) 1.05 (0.77, 1.44) 1.17 (0.81, 1.68) 
      
Sensitivity analysis (H2RA user versus non-user)     
  Additionally adjusted for PPI9 199/1119 (17.8) 689/5394 (12.8) 1.49 (1.25, 1.77) 1.39 (1.16, 1.67) 1.33 (1.07, 1.67) 
  H2RA user vs. PPI user10 199/431 (46.2) 689/1604 (43.0) 1.03 (0.78, 1.36) 1.00 (0.75, 1.33) 0.86 (0.60, 1.24) 
  Adjusted for lifestyle using multiple 
imputation11 
199/1119 (17.8) 689/5394 (12.8) 1.49 (1.25, 1.77) 1.49 (1.24, 1.78) 1.45 (1.22, 1.75) 
  Additionally not adjusted for peptic ulcer 
and oesophagitis12 
199/1119 (17.8) 689/5394 (12.8) 1.49 (1.25, 1.77) 1.47 (1.23, 1.76) 1.42 (1.14, 1.77) 
1 Study matched on age, sex and general practice and model contains obesity, comorbidities in exposure period (including diabetes, coronary heart 
disease, myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, cerebrovascular accident, chronic obstructive 
pulmonary disease, mental illness, liver disease, peptic ulcer, oesophagitis) and other medication use in exposure period (statins, aspirin). 
2 Additionally adjusted for alcohol and smoking. 
3 Medication use in the year prior to diagnosis/index date restricted to individuals with at least 3 years of records. 
4 Medication use in the year from 2 years to 1 year prior to diagnosis/index date restricted to individuals with at least 3 years of records. 
5 Medication use in the year from 3 years to 2 years prior to diagnosis/index date restricted to individuals with at least 4 years of records. 
6 Medication use in the year from 4 years to 3 years prior to diagnosis/index date restricted to individuals with at least 5 years of records. 
7 Medication use in the year from 5 years to 4 years prior to diagnosis/index date restricted to individuals with at least 6 years of records. 
8 Proportion of cases and controls who used H2RA in the year before diagnosis and who had not previously used H2RA.  
9 Additionally adjusted for PPI. 
10 Using only PPI users as an active comparator. 
11 Using multiple imputation to adjust for alcohol and smoking. 
12 Removing the peptic ulcer and oesophagitis adjustment from main model. 
 
Table 4. The association between PPI or H2RA use and the risk of gastric cancer in UK Biobank. 
 Users  Non users Unadjusted 
HR (95%CI) 
Adjusted1 





cancer, n  
Person-
years 
PPI user vs. non-user        
  Main analysis (starting follow-up at 1y) 44 208807  206 1949341 1.53 (1.10, 2.12) 1.28 (0.86, 1.90) 
        
  Male only  29 94195  153 896467 1.43 (0.96, 2.13) 1.14 (0.70, 1.87) 
  Female only  15 114611  53 1052874 1.94 (1.09, 3.47) 1.73 (0.86, 3.45) 
        
  Adenocarcinoma 37 208807  175 1949341 1.52 (1.07, 2.18) 1.18 (0.76, 1.83) 
        
  Gastric cardia 15 208807  86 1949341 1.26 (0.72, 2.18) 0.81 (0.40, 1.64) 
  Gastric non-cardia 14 208807  51 1949341 1.93 (1.06, 3.50) 1.44 (0.68, 3.06) 
        
  Main additionally adjusting for H2RA2 44 208807  206 1949341 1.53 (1.10, 2.12) 1.26 (0.84, 1.88) 
  Main removing adjustment for GORD, 
oesophagitis and peptic ulcer3 
44 208807  206 1949341 1.53 (1.10, 2.12) 1.41 (1.00, 1.98) 
  Main additionally adjusting for year of 
cohort entry4 
44 208807  206 1949341 1.53 (1.10, 2.12) 1.28 (0.86, 1.90) 
        
  Starting follow-up at 2y 30 162955  170 1525464 1.28 (0.86, 1.89) 1.15 (0.73, 1.82) 
  Starting follow-up at 3y 22 117731  122 1105366 1.28 (0.81, 2.02) 1.12 (0.65, 1.92) 
        
Omeprazole user vs. non-user        
  Main analysis (starting follow-up at 1y) 25 122860  225 2035288 1.43 (0.95, 2.17) 1.17 (0.74, 1.85) 
        
Lansoprazole user vs. non-user        
  Main analysis (starting follow-up at 1y) 16 73848  234 2084299 1.49 (0.90, 2.48) 1.21 (0.71, 2.08) 
        
H2RA user vs. non-user        
  Main analysis (starting follow-up at 1y) 4  38517  246 2119632 0.80 (0.30, 2.15) 0.49 (0.16, 1.56) 
1 Adjusted for age at baseline, sex, socioeconomic status, alcohol, smoking, BMI, comorbidities at baseline (including diabetes, GORD, oesophagitis, 
peptic ulcer) and other medication use at baseline (statins, aspirin). 
2 Additionally adjusted for H2RA. 
3 Removing the GORD, oesophagitis and peptic ulcer adjustment from the main model. 
4 Additionally adjusted for year of cohort entry. 
 
Appendix 1: Comorbidities in gastric cancer cases and controls in PCCIU database and UK 
Biobank. 
 PCCIU  UK biobank 
 Cases, n(%) Controls, n 
(%) 





Count  1119 (17.3) 5394 (82.7)  250 471529 
Selected comorbidities      
  GORD1    16 (6.4) 19582 (4.2) 
  Peptic ulcer  15 (1.3) 75 (1.4)  7 (2.8) 5724 (1.2) 
  Diabetes  54 (4.8) 222 (4.1)  22 (8.8) 23821 (5.1) 
  Oesophagitis 7 (0.6) 44 (0.8)  4 (1.6) 1361 (0.3) 
  Coronary heart disease 58 (5.2) 263 (4.9)    
  Myocardial infarction 24 (2.1) 98 (1.8)    
  Heart failure 27 (2.4) 107 (2.0)    
  Peripheral vascular disease 24 (2.1) 97 (1.8)    
  Mental illness 68 (6.1) 322 (6.0)    
  Cerebrovascular disease 46 (4.1) 203 (3.7)    
  Cerebrovascular accident  22 (2.0) 88 (1.6)    
  Chronic obstructive pulmonary 
disease 
51 (4.6) 176 (3.2)    
  Liver disease 3 (0.3) 10 (0.2)    




Appendix 2: The association between drug new use in the year before index date and the risk of gastric 
cancer in PCCIU database. 
   Unadjusted Adjusted1 Fully adjusted2 
 Case, n(%) Control, n(%) OR (95%CI) OR (95%CI) OR (95%CI) 
 
PPI new user vs. PPI non-user 376/1119 (33.4) 235/5394 (4.4) 10.93 (9.01, 13.25) 11.11 (9.14, 13.51) 10.98 (8.47, 14.23) 
Age at index       
  <55 40/97 (41.2) 20/493 (4.06) 15.77 (8.05, 30.92) 17.11 (8.32, 35.18) 14.72 (5.70, 37.99) 
  55-69 146/360 (40.6) 63/1775 (3.6) 19.58 (13.32, 28.80) 21.10 (14.18, 31.38) 18.14 (11.13, 29.57) 
  70+ 190/662 (28.7) 152/3126 (4.9) 7.56 (5.92, 9.65) 7.84 (6.10, 10.07) 8.03 (5.71, 11.31) 
      
H2RA new use vs. H2RA non-user 89/1119 (7.9) 58/5394 (1.1) 8.11 (5.75, 11.43) 8.26 (5.85, 11.68) 9.87 (6.04, 16.15) 
Age at index      
  <55 14/97 (14.4) 5/493 (1.0) 20.32 (5.80, 71.23) 24.22 (6.24, 94.06) 48.34 (4.59, 509.16) 
  55-69 38/360 (10.6) 24/1775 (1.4) 8.52 (4.94, 14.71) 8.81 (5.00, 15.15) 9.40 (4.38, 20.14) 
  70+ 37/662 (5.6) 29/3126 (1.0) 6.07 (3.72, 9.89) 6.33 (3.87, 10.35) 7.88 (3.89, 15.95) 
1 Study matched on age, sex and general practice and model contains obesity, comorbidities in exposure period (including diabetes, coronary heart 
disease, myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, cerebrovascular accident chronic obstructive 
pulmonary disease, mental illness, liver disease, peptic ulcer, oesophagitis) and other medication use in exposure period (statins, aspirin). 
2 Additionally adjusted for alcohol and smoking. 
 
 

